LIMINATUS PHARMA, INC. Cash and Restricted Cash
LIMINATUS PHARMA, INC. (LIMN) had Cash and Restricted Cash of $0 as of 2025-03-31, per its 10-Q filed 2025-06-02.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2025-06-02
- 2025-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0.00.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0.00.
- 2024-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0.00.
- 2023-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $0.00.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-06-02 |
| 2024-12-31 | $0.00 10-Q · filed 2025-06-02 |
| 2024-03-31 | $0.00 10-Q · filed 2025-06-02 |
| 2023-12-31 | $0.00 10-Q · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |